BioSense Inks $68 Million Deal for Neovacs’ Autoimmune Disease Vaccine in China

New Jersey/Suzhou-based BioSense Global has signed an option agreement with Neovacs of France for Neovacs' Phase II-stage IFNα Kinoid therapeutic vaccine candidate, a treatment for lupus and dermatomyositis. Neovacs could receive up to $68 million in upfront and milestone payments, plus sales royalties. Neovacs retains rights for other regions, except for a previously announced South Korea partnership. BioSense also receives first right of refusal in Greater China for any further IFNα Kinoid indications, including type 1 diabetes. Additional terms were not disclosed. More details.... Stock Symbol: (Paris: ALNEV) Share this with colleagues: // //